Editorial: Adenosine pathways in cancer immunity and immunotherapy.
作者信息
Fu Junjiang, Antonioli Luca, El-Far Ali H
机构信息
Key Laboratory of Epigenetics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan, China.
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
出版信息
Front Immunol. 2023 Oct 10;14:1298487. doi: 10.3389/fimmu.2023.1298487. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Adenosine pathways in cancer immunity and immunotherapy.社论：癌症免疫与免疫治疗中的腺苷通路
Front Immunol. 2023 Oct 10;14:1298487. doi: 10.3389/fimmu.2023.1298487. eCollection 2023.
2
Targeting the adenosine pathway for cancer immunotherapy.针对癌症免疫疗法的腺苷途径。
Semin Immunol. 2019 Apr;42:101304. doi: 10.1016/j.smim.2019.101304.
3
Targeting adenosine for cancer immunotherapy.针对癌症免疫疗法的腺苷靶点。
J Immunother Cancer. 2018 Jun 18;6(1):57. doi: 10.1186/s40425-018-0360-8.
4
Rethinking the adenosine-AR checkpoint: implications for enhancing anti-tumor immunotherapy.重新思考腺苷-AR 检查点：增强抗肿瘤免疫治疗的意义。
Curr Opin Pharmacol. 2020 Aug;53:77-83. doi: 10.1016/j.coph.2020.07.003. Epub 2020 Aug 9.
5
Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies.靶向免疫抑制性腺苷信号：潜在免疫治疗联合策略的综述。
Int J Mol Sci. 2023 May 17;24(10):8871. doi: 10.3390/ijms24108871.
6
Biological roles of A-to-I editing: implications in innate immunity, cell death, and cancer immunotherapy.A-to-I 编辑的生物学作用：在先天免疫、细胞死亡和癌症免疫治疗中的意义。
J Exp Clin Cancer Res. 2023 Jun 17;42(1):149. doi: 10.1186/s13046-023-02727-9.
7
CD39/CD73/A2AR pathway and cancer immunotherapy.CD39/CD73/A2AR 通路与癌症免疫治疗。
Mol Cancer. 2023 Mar 2;22(1):44. doi: 10.1186/s12943-023-01733-x.
8
Targeting adenosine and regulatory T cells in cancer immunotherapy.在癌症免疫治疗中靶向腺苷和调节性 T 细胞。
Hum Immunol. 2021 Apr;82(4):270-278. doi: 10.1016/j.humimm.2020.12.005. Epub 2021 Feb 18.
9
Adenosine: The common target between cancer immunotherapy and glaucoma in the eye.腺苷：眼部癌症免疫治疗与青光眼的共同靶点。
Life Sci. 2021 Oct 1;282:119796. doi: 10.1016/j.lfs.2021.119796. Epub 2021 Jul 8.
10
Editorial overview: Cancer 2020 current mechanistic insights into the hypoxia-adenosine-A2A adenosinergic immunosuppressive axis in cancer immunotherapies.编辑概述：《癌症2020》：癌症免疫疗法中缺氧-腺苷-A2A腺苷能免疫抑制轴的当前机制见解
Curr Opin Pharmacol. 2020 Aug;53:iii-v. doi: 10.1016/j.coph.2020.10.012.
引用本文的文献
1
Editorial: Community series in adenosine pathways in cancer immunity and immunotherapy, volume II.社论：癌症免疫与免疫治疗中腺苷途径的社区系列，第二卷。
Front Immunol. 2025 Jan 29;16:1538930. doi: 10.3389/fimmu.2025.1538930. eCollection 2025.
2
Evaluation of ENG/CD105 expression, methylation, immuno-response, and cordycepin (CD) regulation as a novel biomarker of breast invasive carcinoma (BRCA).评估ENG/CD105表达、甲基化、免疫反应及虫草素（CD）调节作为乳腺浸润性癌（BRCA）的一种新型生物标志物。
J Cancer. 2024 Aug 13;15(16):5244-5257. doi: 10.7150/jca.98767. eCollection 2024.
本文引用的文献
1
Targeting adenosine for cancer immunotherapy.针对癌症免疫疗法的腺苷靶点。
J Immunother Cancer. 2018 Jun 18;6(1):57. doi: 10.1186/s40425-018-0360-8.
2
Purinergic regulation of the immune system.嘌呤能免疫系统调节。
Nat Rev Immunol. 2016 Mar;16(3):177-92. doi: 10.1038/nri.2016.4.
3
The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine.实体癌的细胞外液含有具有免疫抑制浓度的腺苷。
Cancer Res. 1997 Jul 1;57(13):2602-5.
Zotero 插件